EGFR Mutations & TKI Therapy

• Focused on stage IV NSCLC patients with EGFR-activating mutations
• Compared survival outcomes with patients receiving non-targeted treatments
• Result : Significantly improved overall survival with TKI therapy
• Impact: Validated the use of genomic real-world data to confirm therapeutic benefit

KRAS + TP53 Co-Mutations & Immunotherapy

• Analyzed prognosis of KRAS-mutant NSCLC patients with and without TP53 co-mutations
• Also examined the treatment effectiveness of immunotherapies is stage IV disease in both these cohorts
• Result 1 : In early-stage disease, co-mutations are linked to worse prognosis whereas there was no survival impact for stage IV disease
• Result 2: Immunotherapy led to improved survival across mutation groups in advanced disease
• Impact: Reinforced the value of immunotherapy regardless of co-mutation context

Advancing Precision Oncology with Integrated RWD

• Showcased the ability to perform integrated clinicogenomic analyses at scale
• Delivered insights into treatment effectiveness, mutation-driven prognosis, and tumor heterogeneity
• Enabled data-driven patient stratification to support personalized care strategies